Assuming that the CRC–CRN is affected by a mutation resulting in the GoF of k-Ras, we investigated the effect on the mutated network of Dabrafenib, a drug that inhibits Raf activity19,46. This evidence concerns the gene KRAS and colorectal carcinoma.